Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec:21:26-34.
doi: 10.1016/j.coviro.2016.07.007. Epub 2016 Aug 3.

Oncolytic herpes simplex virus interactions with the host immune system

Dipongkor Saha  1 , Hiroaki Wakimoto  1 , Samuel D Rabkin  2
Affiliations
Review

Oncolytic herpes simplex virus interactions with the host immune system

Dipongkor Saha et al. Curr Opin Virol. 2016 Dec.

Abstract

Oncolytic viruses (OVs), like oncolytic herpes simplex virus (oHSV), are genetically engineered to selectively replicate in and kill cancer cells, while sparing normal cells. Initial OV infection, cell death, and subsequent OV propagation within the tumor microenvironment leads to a cascade of host responses (innate and adaptive), reflective of natural anti-viral immune responses. These host-virus interactions are critical to the balance between OV activities, anti-viral immune responses limiting OV, and induction of anti-tumor immunity. The host response against oHSV is complex, multifaceted, and modulated by the tumor microenvironment and immunosuppression. As a successful pathogen, HSV has multiple mechanisms to evade such host responses. In this review, we will discuss these mechanisms and HSV evasion, and how they impact oHSV therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Graphic representation of HSV-host immune interactions. [Graphical Abstract]
Figure 2
Figure 2
Schematic overview of host immune responses to oHSV infection.
See this image and copyright information in PMC

References

    1. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14:642–662. * A thorough review describing oncolytic viruses, including oHSV, mechanisms of action and interactions with the immune system and how these can be modulated for anti-tumor immunotherapeutic efficacy. - PMC - PubMed
    1. Chiocca EA, Rabkin SD. Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res. 2014;2:295–300. - PMC - PubMed
    1. Peters C, Rabkin SD. Designing Herpes Viruses as Oncolytics. Mol Ther Oncolytics. 2015;2:15010. - PMC - PubMed
    1. Ott PA, Hodi FS. Talimogene Laherparepvec for the Treatment of Advanced Melanoma. Clin Cancer Res. 2016;22:3127–3131. - PubMed
    1. Suazo PA, Ibanez FJ, Retamal-Diaz AR, Paz-Fiblas MV, Bueno SM, Kalergis AM, Gonzalez PA. Evasion of early antiviral responses by herpes simplex viruses. Mediators Inflamm. 2015;2015:593757. - PMC - PubMed

Publication types

LinkOut - more resources